GC Genome Corporation (340450.KQ) stock: key figures, P/E, revenue and dividend
Health Care · South Korea
GC Genome Corporation financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 25.89 bn KRW | 31.53 bn KRW |
| Gross profit | 11.71 bn KRW | 14.63 bn KRW |
| Operating income | -1.23 bn KRW | 1.24 bn KRW |
| EBIT | -167.31 m KRW | 4.35 bn KRW |
| Net income | -1.26 bn KRW | 4.04 bn KRW |
| Diluted EPS – continuing operations | -53.14 KRW | 171.00 KRW |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About GC Genome Corporation
GC Genome Corporation operates as a clinical genome analysis company in South Korea. It offers hereditary cancer, tissue and liquid biopsy genetic, blood cancer, and homologous recombination deficiency tests under the Green Plan names; Guardant360, a blood genetic profiling test; Guardant Reveal, a liquid biopsy microscopic residual disease detection and recurrence monitoring test; and genetic rare disease testing services for chromosomal microarray, targeted exome sequencing, whole exome sequencing, and diagnostic genome sequencing. The company also provides ai-CANCERCH, an AI algorithm-based multi-cancer early screening test; Jins Sketch, a genetic test for personalized nutrition; Genome Health and Risk Screen that identifies various disease-susceptibility genes; Green Biome for human symbiotic microorganism genetic analysis service; Genome Screen, an optimal genetic test for preemptive action; Telorisk, an indicator of biological age; and drug compatibility DNA test. In addition, it offers G-NIPT, a noninvasive fetal chromosomal abnormality screening test; Prenatal CMA, a diagnostic test for fetal chromosomal abnormalities with higher diagnostic value; i-screen for newborn genetic screening; and dd-cfDNA, a single nucleotide polymorphism test of cell-free nucleic acid derived from organ transplant donors. The company was founded in 2013 and is based in Yongin-si, South Korea.
More stocks
- SAB Finance as (SABFG.PR)
- SR Bancorp, Inc. (SRBK)
- ALX ONCOLOGY HOLDINGS INC (ALXO)
- Indonesia Prima Property Tbk (OMRE.JK)
- Wei Chih Steel Industrial Co Ltd (2028.TW)
- Digia Oyj (DIGIA.HE)
- Putnam Master Intermediate Income Trust (PIM)
- LVMC Holdings (900140.KS)
- Weblink International Inc (6776.TW)
- Whanin Pharm (016580.KS)
- eCloudvalley Digital Technology Co. Ltd. (6689.TW)
- Casa de Bolsa Finamex S.A.B. de C.V (FINAMEXO.MX)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.